QualityStocks'  Instablog

DoMark International, an investment company focused squarely on development of mass market consumer products, is stripping away encumbrances and adding new capabilities for users in the booming mobile device space via their wholly-owned subsidiary, SolaWerks, Inc., with unique and innovative accessory offerings designed to radically improve capability, functionality, and efficiency. DoMark has a simple philosophy which combines diligent evaluation of potential acquisitions with the financial muscle, experienced personnel, and veteran leadership required to streamline operational logistics and optimize market impact.

The company is really making waves in mobile with great concepts like their SolaPad and SolaCase for charging iPad/iPhone devices via the accessory's onboard solar cells, or via USB and direct current connectors. They have new concepts coming down the pipe as well, like the recently announced (May 23) accessory for multi-media (TV) and gaming via DOMK's 29% acquisition of private developer, Imagic Ltd.

DOMK is positioned well to take advantage of the rapidly expanding mobile market, which is especially ravenous in huge spaces like India and China, wielding a solid portfolio of offerings and equipped with the visionary leadership necessary to continue innovating. SolaWerks' IRcharger™ systems for Apple's iPhone and Samsung's Galaxy products are destined to evolve globally into platform-agnostic device solutions and as the mobile device space continues to gain ridiculous traction, an increasingly large accessory side market is cropping up.

The key to making it in the ultra-profitable mobile accessory space is maintaining relevance/functionality with established product lines while continuing to migrate fresh concepts into the pipeline and having the umbrella of DOMK's superb management team will help realize maximum revenue possibilities here. Let's face it, everything is going to mobile and cloud, the platform is an inescapable facet of the future communications and productivity landscape, something which will only grow faster until we hit some kind of major saturation point. Thus, the attendant mobile accessory space is an ideal risk versus reward environment to develop in.

With guys like Andrew Ritchie, DOMK President and CEO, at the helm, you can expect the maximum potential wrung out of the acquisitions and subsidiaries. Ritchie was tapped from Easymed Services Inc., where he boldly led a complete revamping of the medical IT firm into a globally recognized leader in TeleMedicine, as that company's CEO. In the Chairman slot at DOMK we have the eminent Brent Strassler, who brings two decades of private industry and public capital market experience to the table, along with a wide-ranging set of proficiencies that stretches across all the avenues of corporate governance, finance, and the tricky logistics of emerging companies.

These guys know how to restructure and have spent their time in the trenches reorganizing, developing, and expanding private companies, with Strassler in particular noted for his strides across diverse industrial manufacturing, service, and technology fields. Ritchie is former VP of Operations at Canada's top national paper The Globe and Mail and provided dynamic leadership covering all aspects of the business as Publisher of The Winnipeg Free Press (1k staff, revenue of around $120M). Ritchie is a Harvard man (Senior Executive Leadership Program) and comes out of the Queen's University School of Business up in Kingston as well as the McGill Business School in Montreal, an impressive pedigree that clearly signifies a sharp executive with a stranglehold on the 21st century infoscape.

DoMark is also hitting hard in the therapeutic foot care arena via wholly-owned subsidiary, MuscleFoot Inc., tacking noted UFC fighters, Evan Dunham and Igor Pokrajac, to the sponsorship initiative list for their revolutionary Barefoot Science insole technology late last year (Sept 19, 2012). This is the line that kicked off with the signing of 2012 US Olympic track and field team members, Nick Symmonds and Will Claye, for key endorsement contracts last summer, which led to the support of their first UFC fighter, Damarques Johnson. Again, this shows real savvy when it comes to connecting product to end-users in the target market.

To learn more, visit the DoMark International Web site at DoMarkIntl.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

Some call it the Frankenstein revolution, but the fact is that it heralds what may become one of the most important developments in 21st Century medical science. It's the use of stem cell technology to build living organisms in the laboratory, paving the way for possible customized biological organ and tissue factories that could someday eliminate the need for donors. No longer science fiction, the technology to produce viable tissues and body parts is already under development.

However, there is side to the science, represented by California biotech company VistaGen Therapeutics, that is separate but no less important than the generation of replacement parts for damaged organs. It's the creation of living tissues for the testing of drugs, allowing a degree of detailed testing and analysis superior in many ways to traditional animal tests or human trials. It's a form of testing done right in the lab, observable at the cellular and even molecular level, providing detail unavailable any other way. In addition, it can be done at the earliest stages in drug development, long before committing to the time and expense of formal trials or actual marketing, potentially saving major pharmaceutical companies millions or even billions of dollars.

VistaGen Therapeutics has developed a proprietary pluripotent stem cell technology for use in the discovery, rescue, and development of novel drug candidates. These are drugs that have been shown to be effective, but which had to be shelved late in the game due to heart or liver toxicity, a common problem with new drugs. A pharmaceutical company may have spent a fortune on developing a drug, but it now sits on the shelf, its possible value essentially lost.

Using its Human Clinical Trials in a Test Tube bioassay system, VistaGen can now take such drugs and potentially solve the toxicity issues right in the lab. The company's strategy is to use their technology to build a pipeline of drug rescue variants, proprietary new small molecule drug candidates, in collaboration with contract drug development service companies. VistaGen plans to have economic participation rights to each and every drug it develops, which should benefit its bottom line as well as its shareholders.

For additional information, visit VistaGen.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

International provider of end-to-end eCommerce solutions, PFSweb announced the appointment of Shin Nagakura to its Board of Directors. Non-employee Director Timothy W. Murray is set to retire from the board effective immediately.

Nagakura is currently Director of transcosmos inc. (TSE: 9715) ("TCI"), a leading Japanese business process-outsourcing firm. His appointment will fulfill a condition of the strategic relationship that PFSweb and TCI entered into on May 15, 2013, which states that a TCI representative will sit on PFSweb's Board.

"Adding Mr. Nagakura to the Board is an important step in building and maximizing our relationship with transcosmos," commented Mike Willoughby, CEO of PFSweb. "His presence will help us execute on our goal to become a truly global end-to-end multi-channel eCommerce service provider. By combining our iCommerce solution with TCI's market capabilities, we will not only create opportunities for PFSweb clients to enter the fast-growing Asian market, but also drive revenue growth by providing eCommerce services for Asian companies looking to expand into the U.S and Europe."

Nagakura brings over 15 years of experience investing in and advising technology companies to TCI's Silicon Valley office. His resume includes companies such as RealNetworks, Brightcove, and AskJeeves. Most recently Nagakura held a position for ten years at Recruit Co. Ltd., a marketing services, internet media, and publishing company. Additionally Nagakura serves on the Board of Directors of Merlin Information Systems, Ltd., and Become, Inc., a leader in e-commerce and online comparison-shopping. He graduated from Sophia University in Tokyo with a B.A. in International Studies in 1986.

PFSweb is currently engaged by iconic brands to help enable and manage customized eCommerce initiatives. To learn more about PFSweb, please visit: PFSweb.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net